Ongoing research, including a study with patient-derived iPSCs showing the effectiveness of nocodazole in increasing dysferlin levels in cells, indicates promising directions for future dysferlinopathy treatments [223]. This evidence concerns the gene DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin.